“A randomized, double-blind study of the effects of omega-3 fatty acids (Omegaven™) on outcome after major liver resection”

Michael Linecker1,2, Perparim Limani1,2, Florin Botea4, Irinel Popescu4, Ruslan Alikhanov5, Michail Efanov5, Pavel Kim5, Igor Khatkov5, Dimitri Aristotele Raptis1,2, Christoph Tschuor1,2, Beatrice Beck-Schimmer3, John Bonvini3, Andrea Wirsching1,2, Philipp Kron1,2, Ksenija Slankamenac1,2, Bostjan Humar1,2, Rolf Graf1,2, Henrik Petrowsky1,2 and Pierre-Alain Clavien1,2*

Abstract

Background: The body is dependent on the exogenous supply of omega-3 polyunsaturated fatty acids (n3-PUFA). These essential fatty acids are key players in regulating metabolic signaling but also exert anti-inflammatory and anti-carcinogenic properties. The liver is a major metabolic organ involved in fatty acid metabolism. Under experimental conditions, n3-PUFA exert a beneficial effect on hepatic steatosis, regeneration and inflammatory insults such as ischemic injury after surgery. Some of these effects have also been observed in human subjects. However, it is unclear whether perioperative administration of n3-PUFA is sufficient to protect the liver from ischemic injury. Therefore, we designed a randomized controlled trial (RCT) assessing n3-PUFA (pre-) conditioning strategies in patients scheduled for liver surgery.

Methods/Design: The Omegaven™ trial is a multi-centric, double-blind, randomized, placebo-controlled trial applying two single doses of Omegaven™ or placebo on 258 patients undergoing major liver resection. Primary endpoints are morbidity and mortality one month after hospital discharge, defined by the Clavien-Dindo classification of surgical complications (Ann Surg 240(2):205–13, 2004) as well as the Comprehensive Complication Index (CCI) (Ann Surg 258(1):1–7, 2013). Secondary outcome variables include length of Intensive Care Unit (ICU) and hospital stay, postoperative liver function tests, fatty acid and eicosanoid concentration, inflammatory markers in serum and in liver tissue. An interim analysis is scheduled after the first 30 patients per randomization group.

Discussion: Long-term administration of n3-PUFA have a beneficial effect on metabolism and hepatic injury. Patients often require surgery without much delay, thus long-term n3-PUFA uptake is not possible. Also, lack of compliance may lead to incomplete n3-PUFA substitution. Hence, perioperative Omegaven™ may provide an easy and controllable way to ensure hepatic application of tic protection.

Trial registration: ClinicalTrials.gov: ID: NCT01884948, registered June 14, 2013; Institution Ethical Board Approval: KEK-ZH-Nr. 2010–0038; Swissmedic Notification: 2012DR3215.

Keywords: Omega3- polyunsaturated fatty acids (n3-PUFA), Omegaven™, Major liver surgery, Clavien-Dindo complication score, Comprehensive Complication Index (CCI)
Background
Before the 1930s, dietary fat was thought to be simply a source of calories which could be exchanged by e.g. carbohydrates. In 1930, Mr. & Mrs. Burr discovered that specific fatty acids were critical to health [3]. Linoleic acid was the first essential fatty acid described to restore growth deficits and prevent dermatitis in rats given fat-free diets [3].

In the late 1970s Bang & Dyerberg have associated the exceptionally low prevalence of coronary heart disease among Greenland inuits with their high intake of omega-3 polyunsaturated fatty acids (n3-PUFA) from marine sources [4]. To date, after more than 40 years of intense research, an abundance of beneficial effects have been attributed to n3-PUFA.

Undoubtedly, the liver is a central target of n3-PUFA given that this organ maintains systemic metabolic control. Preclinical data suggest that supplementation of n3-PUFAs may be beneficial in operations involving steatotic livers [5], after major liver resection and subsequent regeneration [6], and during inflammatory insults such as ischemic injury [5, 7, 8]. Moreover, some beneficial effects have been documented also in human subjects [9]. The protective effect of n3-PUFA supplementation is being primarily investigated in a long term setting, which seems not very appropriate for patients scheduled for liver resection. First, surgery should not be delayed to reach a comparable duration of n3-PUFA oral administration. Second, intravenous perioperative administration renders an easy and controllable way of protection and circumvents problems of compliance.

Major liver surgery can incur serious postoperative complications, with ischemic injury and regeneration being two major determinants of the operative outcome. Fatty liver additionally increases postoperative complications, as it inhibits regeneration and displays explicit sensitivity towards ischemic injury. More so, fatty liver can progress to steatohepatitis and hepatocellular carcinoma, a major indication for liver surgery. Thus, steatosis indirectly increases the need for surgery whilst limiting its application. Perioperative treatment with n3-PUFA, on the other hand, may reduce steatosis, mitigate ischemic injury and promote regeneration, effects likely of great benefit for fatty liver. Therefore, n3-PUFA are expected to lower the incidence and/or the level of complications following liver surgery.

In this trial, we will assess the use of n3-PUFA as a potential (pre-)conditioning strategy for the reduction of postoperative complications after major liver surgery. Omegaven™ is the first n3-PUFA formulation approved for the intravenous use in humans. In the patient collective scheduled for liver resection, parenteral administration seems more appropriate for reasons mentioned above. Owing to the favorable toxicity profile, the ease of application, and the general health-promoting effects, (pre-)conditioning through n3-PUFA has the potential to become a standard strategy to improve the outcome of major liver surgery (Table 1).

Methods/Design
The Omegaven™ trial is a prospective, multi-centric, double-blind, randomized, placebo-controlled trial assessing the effect of two peri-operative doses of Omegaven™ (100 ml each dose) on morbidity and mortality after major liver resection. The trial is open to all high-volume hepatobiliary centers performing at least 30 cases/year potentially eligible for this study. So far, three centers are recruiting patients. Ethics approval for the main center Zurich was obtained from Professor Edith Schmid, for Bucharest from Professor Mihai Voiculescu and for Moscow from Professor Byakhov M.Y. Additional centers

### Table 1 Study synopsis

| Sponsor investigator | Prof. Pierre-Alain Clavien, MD PhD |
|----------------------|-----------------------------------|
| Study product        | Omegaven™, 100 ml intravenously administered at the evening before and during liver resection |
| Primary endpoint     | Postoperative morbidity and mortality determined by the Clavien-Dindo classification of surgical complications and the Comparative Complication Index (CCI) 1 month after hospital discharge. |
| Secondary endpoints  | Main center: Serum samples: postoperative peak AST and ALT, fatty acids and n3 PUVA concentration, inflammatory markers Liver biopsy: histology (necrosis, apoptosis), inflammatory markers, hepatic fatty acid and n3 PUVA content Main center and external centers: Duration of hospitalization and ICU stay Hematology: hemoglobin, hematocrit, leukocytes, platelets, INR Chemistry: triglycerides, bilirubin, AST, ALT, ALKP, creatinin, CRP |
| Methodology          | Randomized, double-blind, placebo controlled |
| Clinical phase       | Phase III (new indication for Omegaven™) |
| Study duration       | 3 years (start: July 2013) |
| Study centers        | Multi-center (Zurich, Bucharest, Moscow) |
| Number of subjects   | 258 patients |
| Main inclusion criteria | Adult (more than 18 years) requiring liver resection of at least 1 segment or multiple wedge resections (≥3); no coagulopathy (INR ≤ 1.2, platelets ≥ 150,000 × 10^3/μl) |
| Main exclusion criteria | Liver resections < 1 segment, wedge resections <3); coagulopathy (INR > 1.2, platelets < 150,000 × 10^3/μl); hypotriglyceridemia (>5.0 mmol/l); liver cirrhosis; severe renal failure (estimated GFR < 30 ml/min/1.73 m²); pregnancy. |

ClinicalTrial.gov ID: NCT01884948
are open to start recruiting after local regulatory approval. In total 258 patients will be recruited and an interim analysis performed when 30 patients from each group have successfully reached the primary study endpoint.

**Study objectives**

The study aims at a 30 % reduction in the Comprehensive Complication Index (CCI) or a 30 % reduction of any complication according to the Clavien- Dindo score [1]. Secondary endpoints include duration of hospitalization and Intensive Care Unit (ICU) stay, readmission rates, postoperative peak ALT (alanine aminotransferase) and AST (aspartate aminotransferase) serum levels (area under the curve), fatty acid and n3-PUFA concentration in serum and liver tissue as well as assessment of inflammation in liver biopsies. N3-PUFA concentrations in sera and studies on liver biopsies will be measured and performed in the main center only.

**Inclusion criteria**

- Requiring liver resection of at least one segment or multiple wedge resections (≥ 3)
- > 18 years of age
- Understand local language
- No coagulopathy (international normalized ratio (INR) < 1.2, platelets > 150,000 × 10^3/μl)

**Exclusion criteria**

- Liver resections < 1 segment
- Wedge resections (< 3)
- Liver cirrhosis on histology
- Coagulopathy (INR > 1.2, platelets < 150,000 × 10^3/μl)
- Hypertriglyceridemia (> 5.0 mmol/l)
- Hypersensitivity or allergy to Omegaven™ or any fish oil or lipid emulsions
- Known allergy to egg protein
- Pregnancy
- Nursing women
- Renal failure (estimated GFR < 30 ml/min/1.73 m2)
- Medication impairing platelet aggregation

**Study product**

Omegaven™ is a fish oil-based lipid emulsion approved for parenteral nutrition provided by Fresenius Kabi (Swissmedic approval number: 54750). Both study drug and placebo (0.9 % saline) are administered in 100 ml equally shaped bottles with a maximum infusion rate of 0.5 ml/kg/hour on the evening before surgery and during surgery.

**Blinding**

In this double-blind RCT surgeons and nurses are blinded. Since the placebo is transparent and Omegaven™ is a white emulsion, blinding is done with a black bag covering the study medication along with opaque infusion lines. Blinding is performed by a study-independent person, which is also responsible for randomization. This person is not involved in the study otherwise. Before intravenous administration, this person has to ensure that blinding is done properly and the patients and study personnel cannot detect the color of the infusion. An emergency code break will be available to the investigator. This code break should be opened only in situations where the identity of the investigational product must be known by the investigator in order to provide appropriate medical treatment.

**Randomization**

A block randomization is performed by the CTC (Clinical Trial Center) Zurich to minimize a potential center bias. In detail, the above-mentioned independent person (i.e. responsible for the blinding) of each center receives a block randomization list which is adjusted to the case load of the center. As soon as a patient is included, a “randomization- button” in the electronic case report form (eCRF) will allocate the patient to the randomization-number in the block randomization list.

**Recruitment, study procedures and data collection**

Patients potentially eligible for the study are first seen in the outpatient clinic where demographic data and medical history are evaluated and physical examination is performed. Eligible patients (according to the inclusion/exclusion criteria) will be asked whether they are willing to participate in the study. Those willing to participate will be asked to provide a written informed consent. Patients having given written consent will be further evaluated for eligibility. The preoperative workup will be performed according to local practice. Routine laboratory tests as well as the mentioned laboratory parameters will be determined (including Serum TG, INR and platelet count). Women will undergo a pregnancy test. If serum measurements are within a normal range and female patients are not pregnant, randomization can be performed the day before surgery. Subsequently, the first infusion of Omegaven™ or Placebo is administered. One hour after infusion start, safety blood samples assessing circulating TG levels, platelets and INR are taken. Major deviations from baseline levels along with clinical symptoms will terminate study drug application. The second dose starts the following morning during induction of anesthesia in the operating theatre. As done during the first administration, safety blood samples are obtained one hour after infusion start followed by another blood sample at the end of infusion. Liver biopsies and blood...
samples for the determination of inflammatory markers and n3-PUFA concentrations are assigned to the main center only. The last perioperative blood sample is taken 24 hours after finishing the administration of the second dose. Further blood samples rely on routine clinical practice of the participating centers. According to the definition of the Clavien Dindo score [1] of surgical complications and the CCI [2], patients will reach the primary study endpoint one month after hospital discharge. All data including adverse and serious adverse events (AE and SAE) will be prospectively collected using a software specifically designed for the purpose and needs of this study (secuTrial™). SAE from all centers are reported to the Sponsor- Investigator of the trial who is responsible for further reporting to the regulatory authorities (IEC and Swissmedic) (Figs. 1 and 2).

**Sample size**

We hypothesized that in 117 patients two intravenous infusions of Omegaven™ will protect the liver causing effective reduction of the post-operative complication rates (CCI) by 30 % when compared to the 117 placebo patients.

The sample size of 117 patients per randomized group (234 in total) was calculated based on the following parameters using the patient cohort of major liver resections at the University Hospital Zurich:

- Percentage of complications for placebo group: 65 %
- Mean CCI in major resections is 17 (standard deviation: 15.9)
- Percentage of complications for Omegaven™ group: 30 % reduction of complications and/or CCI
- \( \alpha: 0.05 \)
- Power \((1-\beta)\): 0.8
- 2-sided test

Expected differences in proportions are based on data derived from the literature. Such a statistically significant reduction of the complication rate is considered to be clinically significant. A 10 % dropout rate is relatively common for liver resection, we thus have increased the sample size to 258 patients in total for both groups.

**Ethics**

The study is conducted in accordance with principles enunciated in the current version of the Declaration of Helsinki, the guidelines of Good Clinical Practice (GCP) issued by the International Conference on Harmonization (ICH), and Swiss regulatory authority's requirements. The study protocol, patient information and consent form are approved by the Independent Ethics Committee (IEC) in agreement with local legal requirements at each study site. Any amendments to the protocol, other than administrative ones, must also be approved by these committees.

**Discussion**

The goal of this RCT is to assess for major liver surgery the hepato-protective effects of two perioperative infusions of an n3-PUFA preparation. This type of surgery is inherently associated with a relatively high complication rate pending on the complexity of the procedure. Therefore, pharmacological strategies to protect the remnant liver during this traumaperiod are in the focus of interest.

---

**Fig. 1** Study flow chart overlooking the study period schematically. (BS: blood sample, OP: Day of operation, POD: Post- operative day)
The major point of interest is if two single perioperative doses will suffice to induce the postulated protective effect. A recent kinetic study in healthy volunteers revealed that a single oral dose of n-3 PUFA is able to rapidly induce a shift in the n-3 PUFA plasma profile within a few hours [10]. Also, short term administration just prior to ischemic insults was strongly protective in animal models [7]. These findings support our hypothesis that one dose of n3-PUFA as pre-conditioning (the day before surgery) followed by another continuous infusion during liver surgery elevates n3-PUFA plasma levels to potentially therapeutic levels.

The study medication, Omegaven™ is approved by Swissmedic since years for the indication of parenteral nutrition and is thus the n3-PUFA preparation of choice for intravenous use. In this trial, the best comparative placebo would contain the same intravenous emulsion without n-3 PUFA. However, from a pharmaceutical point of view such a placebo is not feasible, as it would require its own clinical safety assessment. Hence, saline was chosen.

Given the liver-specific defatting effect combined with protective effects for surgical trauma (i.e. mitigation of ischemia-reperfusion injury and improvement of regeneration) n3-PUFA appear to be a promising and feasible strategy for safer liver surgery.

Abbreviations
AE: Adverse event; ALT: Alanine transaminase; AST: Aspartate transaminase; CTC: Clinical trials center; eCRF: Electronic case report from; GCP: Good clinical practice; GFR: Glomerular filtration rate; ICH: International conference on harmonization; ICU: Intensive care unit; IEC: Independent ethics committee; IIT: Investigator initiated trial; INR: International normalized ratio; n3-PUFA: Omega3–polyunsaturated fatty acids; RCT: Randomized controlled trial; SAE: Serious adverse event; TG: Triglycerides.

Competing interests
The authors declare that they have no competing interest. The trial is an investigator initiated trial (IIT) without competing interest of any pharmaceutical company, including Fresenius providing the study product.

Authors’ contributions
ML, PL, HP, RG, BH, CT and PAC drafted the manuscript. ML, BH, and PAC designed the protocol and co-authored the writing of the manuscript. ML and DR performed the study design and KS the calculation of the sample size of the study. FB and IP passed the study protocol through regulatory authorities in Bucharest, Romania and are responsible investigators at this site. RA, ME, PaK and IJ passed the study protocol through regulatory authorities in Moscow, Russia and are responsible investigators at this site. BBS and JB designed a standardized anesthesia protocol and are study-co-investigators for anesthesia. AW and PK designed the mode of randomization and blinding of the study. All authors were involved in editing the manuscript and approved the final text of the manuscript. ML and BH revised the manuscript.

Acknowledgement
The trial is supported by the KFSP (Klinischer Forschungsschwerpunkt) grant “non-resectable liver tumors– from palliation to cure”.

Author details
1. Swiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital Zurich, Zurich, Switzerland.
2. Department of Surgery & Transplantation, University Hospital Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland.
3. Department of Hepatology, University Hospital Zurich, Zurich, Switzerland.
4. Center of General Surgery and Liver Transplantation, Fundeni Institute Bucharest, Bucharest, Romania.
5. Department of Liver and Pancreatic Surgery, Moscow Clinical Scientific Center, Moscow, Russia.

Received: 6 February 2015 Accepted: 3 August 2015
Published online: 14 August 2015

References
1. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
2. Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013;258(1):1–7.
3. Burr GO, Burr MM. Nutrition classics from The Journal of Biological Chemistry 82:345–67, 1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. Nutr Rev. 1973;31(8):248–9.
4. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet. 1978;2(8081):117–9.
5. El-Badry AM, Moritz W, Contaldo C, Tian Y, Graf R, Clavien PA. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. Hepatology. 2007;45(4):655–63.
6. Marsman HA, de Graaf W, Heger M, van Golen RF, Ten Kate FJ, Bennink R, et al. Hepatic regeneration and functional recovery following partial liver resection in an experimental model of hepatic steatosis treated with omega-3 fatty acids. Br J Surg. 2013;100(5):674–83.
7. Raptis DA, Limani P, Jang JH, Ungethüm U, Tschuor C, Graf R, et al. GPR120 on Kupffer cells mediates hepato-protective effects of omega-3 fatty acids. J Hepatol. 2014;60(3):625–32.
8. El-Badry AM, Jang JH, Elsherbiny A, Contaldo C, Tian Y, Raptis DA, et al. Chemical composition of hepatic lipids mediates reperfusion injury of the macrosteatotic mouse liver through thromboxane A2. J Hepatol. 2011;55(6):1291–9.
9. Clavien PA, Oberkofler CE, Raptis DA, Lehmann K, Rickenbacher A, El-Badry AM. What is critical for liver surgery and partial liver transplantation: size or quality? Hepatology. 2010;52(2):715–29.
10. Schuchardt JP, Schneider I, Willenberg J, Yang J, Hammock BD, Hahn A, et al. Increase of EPA-derived hydroxy, epoxy and dihydroxy fatty acid levels in human plasma after a single dose of long-chain omega-3 PUFAs. Prostaglandins Other Lipid Mediat. 2014;109:111–23–31.
11. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.